Population Genomic Screening for 3 Conditions Likely Cost-Effective
Genomic screening for Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial hypercholesterolemia likely cost-effective for adults younger than 40 years
Genomic screening for Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial hypercholesterolemia likely cost-effective for adults younger than 40 years
The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.
Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.
Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.
Receipt of neoadjuvant vs adjuvant chemotherapy did not differ significantly by clinical nodal stage.
For patients with low-grade residual disease, complete response rate was 70% with UGN-101
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
Findings may inform surveillance strategies and improve treatment outcomes.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.